Originally organIzed around providing human-based drug response profiles in advance of clinical trials, AnaBios has evolved to provide highly valuable, predictive human data in advance of clinical trials, ensuring the selection of the most effective and safest drugs: reducing the time and expense related to clinical trial failures. Through its proprietary technology, based on the use of human donor organs and tissues, AnaBios studies ex-vivo human responses to drugs and further investigates the molecular and functional basis of relevant human physiology. Partnering with Fortune 500 pharmaceutical companies and universities, the firm speialzies in cardiac disease and safety, pain, PKD kidney disease and neurodegeneration. AnaBios markets its products and services directly, as well as through distributors and partners worldwide and also drives an internal drug discovery platform through engagementof of in-licensed programs from pharmaceutical firms and academia.
